Comment on

• Adjuvant therapy for premenopausal women with breast cancer: is it time for another paradigm shift?

  Pritchard KI. Pritchard KI. J Clin Oncol. 2002 Dec 15;20(24):4611-4. doi: 10.1200/JCO.2002.20.24.4611. J Clin Oncol. 2002. PMID: 12488402 No abstract available.
• Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.

  Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert M, Haider K, Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Steger G, Wette V, Samonigg H; Austrian Breast and Colorectal Cancer Study Group Trial 5. Jakesz R, et al. J Clin Oncol. 2002 Dec 15;20(24):4621-7. doi: 10.1200/JCO.2002.09.112. J Clin Oncol. 2002. PMID: 12488405 Clinical Trial.
• Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.

  Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B; Zoladex Early Breast Cancer Research Association Study. Jonat W, et al. J Clin Oncol. 2002 Dec 15;20(24):4628-35. doi: 10.1200/JCO.2002.05.042. J Clin Oncol. 2002. PMID: 12488406